Alentis Therapeutics (Series D)
Funding Details
- Awarder
- Inbox
- Date Award
- November 12, 2024
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $181,400,000
Company Info
- Traction
- FDA clearance obtained for ALE.P02, clinical trials expected to commence in Q1 2025.
- Founders
- Roberto Iacone
- Company Description
- Alentis Therapeutics is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumours. The company is pioneering anti-CLDN1 ADCs and antibodies to modify and reverse the course of select diseases.
- Market
- Clinical-stage oncology
- Location
- Basel, Switzerland
- Coinvestors
- Novo Holdings, Jeito Capital, Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital, Avego Bioscience Capital, RA Capital Management, Morningside Venture Investments, BB Pureos, BPI France